Seponering på grund af kliniske eller laboratoriemæssige bivirkninger var mindre hyppig blandt irbesartanbehandlede patienter (3, 3%) end blandt placebobehandlede (4, 5%).
Discontinuation due to any clinical or laboratory adverse event was less frequent for irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%).